Investor68 schreef op 3 augustus 2015 00:25:
[...vAs far as we know to this date, Filgotinib does not
have any of the risks that you associated with tofacitinib such as "immunosuppression, liver damage, cancer and gastro-intestinal perforations." Therefore, your comment is actually misleading. You should not compare Filgotinib to Tofacitinib in the manner in which you did it. It is very unprofessional, given that you call yourself a "midsize investor." I suggest that you should do a better and more objective research on filgotinib. Galapagos has a lot of potential. If we take into account the major products in Galapagos' pipeline, I think that most fair-minded people would agree that Galapagos' current share price (60,65 dollars) is significantly under
valued. If Galapagos were to be an American company, with all the fantastic results the company has produced so far, it would have been trading at somewhere between 100 to 150 dollars by now. It seems as if European pharmaceutical companies tend to get lower valuations than their American counterparts and this is not fair. This practise must be corrected!